Atelerix Seed
4 known investors
Atelerix develops hypothermic hydrogel encapsulation technology that stabilises and preserves fresh cells, tissues, and blood at room temperature, eliminating the need for cryopreservation and cold-chain logistics. Its plant-based, xeno-free kits (such as CytoStor, BeadReady, and STORganoid) serve research and clinical labs shipping live cell material, organoids, and 3D cell models.
BiotechMedical DevicesNew Materials
Investors Β· 4
Frequently asked questions
- What does Atelerix Seed do?
- Atelerix develops hypothermic hydrogel encapsulation technology that stabilises and preserves fresh cells, tissues, and blood at room temperature, eliminating the need for cryopreservation and cold-chain logistics. Its plant-based, xeno-free kits (such as CytoStor, BeadReady, and STORganoid) serve research and clinical labs shipping live cell material, organoids, and 3D cell models.
- Who are Atelerix Seed's investors?
- Atelerix Seed's investors include Cambridge Angels group, Future Planet Capital, O2h Ventures, UK Innovation & Science Seed Fund.